RVNC News and Press, Revance Therapeutics Inc. From 12/23/19

Introduction I recently wrote an article about Revance Therapeutics' ( RVNC ) long-acting DAXI (DaxiBotulinumToxinA) and how the Phase III data was compelling enough to make me open a long position in RVNC. As an investor, I think it is paramount to always fully assess any competition that...

Editor's note: Seeking Alpha is proud to welcome Robert Falcone as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » Introduction L...

DaxibotulinumtoxinA for Injection (DAXI) demonstrated prolonged duration of response for glabellar line reduction Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today an...

Wednesday brought some holiday cheer to Wall Street, as investors got out of the gloomy mood on hopes that their initial fears about a prolonged trade war between the U.S. and China might prove to have been overblown. Some reports suggested that the two nations might be closer to an early deal t...

Gainers:  Protagonist Therapeutics (NASDAQ: PTGX ) +63% . More news on: Protagonist Therapeutics, Inc., Arbutus Biopharma Corporation, Kodiak Sciences Inc., Stocks on the move, Read more ...

Shares of Revance Therapeutics (NASDAQ: RVNC) are under pressure after management announced the pricing of a secondary offering. Investors dismayed by the pricing of the offering have hammered the biotech stock 16.4% lower as of 12:07 p.m. EST on Wednesday. Revance shares had been climbin...

Revance Therapeutics (NASDAQ: RVNC )  -16%  on pricing equity offering. More news on: Revance Therapeutics, Inc., Outlook Therapeutics, Inc., G-III Apparel Group, Ltd., Stocks on the move, Read more ...

Revance Therapeutics (NASDAQ: RVNC ) has priced its public offering of 6.5M common shares at $17.00 per share, for expected gross proceeds of ~$110.5M. More news on: Revance Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Gainers: HQY   +11.9% . RAPT   +8.2% . CIH   +8.2% . SIGA   +5.0% . NPO   +4.8% . More news on: HealthEquity, Inc., RAPT Therapeutics, Inc., China Index Holdings Limited, Stocks on the move, Read more ...

Bausch Health Companies (NYSE: BHC ) initiated with Neutral rating and C$40 (7% upside) price target at Goldman Sachs. Shares up  2%  premarket. More news on: Bausch Health Companies Inc., Centogene N.V., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ....